A Phase 2 interventional study of CRD-4730 and Placebo in CPVT1, Heart Defects, Congenital and Heart Diseases, sponsored by Cardurion Pharmaceuticals, Inc.. Terminated at 11 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Cardurion Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 2 cohorts in which participants with CPVT will participate in a 3-period, randomized 2-sequence study. Each participant will receive 2 different doses of CRD-4730 and 1 dose of matching placebo, with each study drug administered as a single dose.
991 studies on the registry are indexed under Heart Defects, Congenital; 251 are open to participants now.
This study's enrollment of 7 is below the median of 60 across 507 interventional studies indexed under Heart Defects, Congenital.
Browse Heart Defects, Congenital studies →Cardurion Pharmaceuticals, Inc. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CRD-4730 Dose 1 capsule
Drug: CRD-4730
CRD-4730 Dose 2 capsule
Drug: CRD-4730
Placebo capsule to match CRD-4730
Drug: Placebo
Oral CRD-4730 in capsule form
Placebo to match CRD-4730 in capsule form
Treatment Emergent Adverse Events (TEAEs)
The number of participants with TEAEs including drug-related AEs, serious AEs (SAEs), and AEs leading to study drug discontinuation will be assessed.
Time frame: Baseline to Day 22
Changes in Laboratory Assessments
The number of participants who have normal/ abnormal values at Baseline compared to normal/ abnormal values post-Baseline will be assessed for hematology, serum chemistry and urinalysis.
Time frame: Baseline to Day 15
Changes in Vital Signs Measurement: Systolic and Diastolic blood pressure
Percent change from Baseline to post Baseline will be assessed for systolic and diastolic blood pressure
Time frame: Baseline to Day 15
Changes in Vital Signs Measurement: Pulse Rate
Percent change from Baseline to post Baseline will be assessed for pulse rate
Time frame: Baseline to Day 15
Changes in Vital Signs Measurement: Respiratory Rate
Percent change from Baseline to post Baseline will be assessed for respiratory rate
Time frame: Baseline to Day 15
Changes in Vital Signs Measurement: Body Temperature
Percent change from Baseline to post Baseline will be assessed for body temperature
Time frame: Baseline to Day 15
Changes in Physical Exam
General physical exams will be carried out to detect any abnormalities in the cardiovascular, respiratory and other body systems
Time frame: Baseline to Day 22
Changes in Electrocardiogram (ECG) Measurements
Number of participants who have normal/abnormal ECG measurements at Baseline will be compared to normal/abnormal ECG measurement post Baseline
Time frame: Baseline to Day 22
Change in Ventricular Arrhythmia (VA) score during Exercise Stress Test (EST)
The VA score is a physician administered score on a scale of 0-5 with higher numbers being worse.
Time frame: Baseline to Day 1
Change in Ventricular Arrhythmia (VA) score during Exercise Stress Test (EST)
The VA score is a physician administered score on a scale of 0-5 with higher numbers being worse.
Time frame: Baseline to Day 8
Change in Ventricular Arrhythmia (VA) score during Exercise Stress Test (EST)
The VA score is a physician administered score on a scale of 0-5 with higher numbers being worse.
Time frame: Baseline to Day 15
Assessment of PK effect
Plasma concentrations of CRD-4730 over time for each treatment period
Time frame: Baseline through Day 15
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CRD-4730
Cardurion Pharmaceuticals, Inc.